Evaluating the Pieces in Big Pharma's Manufacturing Investments - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating the Pieces in Big Pharma's Manufacturing Investments
The pharmaceutical majors target biologics and emerging markets in their manufacturing expansion activities and plans.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 38-41

Eli Lilly. In April 2013, Eli Lilly indicated it plans to invest an additional $180 million in the company’s insulin manufacturing operations in Indianapolis, Indiana. The investment is in addition to the company’s November 2012 announcement for a $140-million expansion of the company’s Indianapolis insulin-manufacturing operations. Eli Lilly is proposing several other ancillary investment projects totaling about $80 million, including a $40-million product-inspection center. The latest $180-million proposed investment would add a second insulin cartridge-filling line and increase its insulin-active-ingredient manufacturing capacity through productivity enhancements. In addition, Eli Lilly is investing EUR 330 million ($436 million) in a new biopharmaceuticals facility at its Kinsale campus in Cork, Ireland, according to a Feb. 27, 2012 IDA Ireland press release.

Merck & Co. Earlier this year, Merck & Co. opened a new $120-million, 75,000-m2 pharmaceutical manufacturing facility in Hangzhou, China. The facility has capacity of up to 16 high speed lines to package pharmaceutical tablets and sterile products. Annual packaging capacity is more than 300 million packages. The facility builds on other recent investment by Merck in China. In 2011, the company established its Asia R&D headquarters in Beijing and committed to invest more than $1.5 billion in R&D in China during the next several years.

AstraZeneca. In June 2013, AstraZeneca announced that Cambridge, United Kingdom will be the location for the company’s new UK-based global R&D center and corporate headquarters. The new 330 million ($507 million) facility in Cambridge will bring together AstraZeneca’s small-molecule and biologics R&D activity. The purpose-built facility, which will be located in the Cambridge Biomedical Campus, is part of the company’s previously announced plan to create strategic global R&D centers in the UK, US, and Sweden by 2016. The company is also proceeding with further restructuring activity, which entails an estimated global headcount reduction of about 5050 over the 2013-2016 period. AstraZeneca also moved forward with two key production facilities during 2012 in China (Taizhou) and Russia (Vorsino) to supply products to both markets locally. These sites are intended to begin phased commercial production in 2014.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here